RelīOx Corporation

ReliOx Corporation is a U.S.-based advanced materials and medical technology company with a clean oxidation platform for on-demand generation of pH-neutral aqueous chlorine dioxide. The ReliOx platform enables safe, controlled oxidation at the point of use without acids, electricity, or hazardous intermediates—addressing long-standing limitations that have historically prevented chlorine dioxide from being used routinely in medical and operational environments. ReliOx directly supports the important core objectives aligned with MTEC members: improving trauma care, reducing infection risk, enabling care in austere and resource-constrained settings, and accelerating transition of dual-use technologies from non-regulated markets into regulated medical and defense applications. The platform’s defining feature is not a new chemical agent, but a novel generation method that produces true chlorine dioxide only at the moment of use, in a neutral pH aqueous form compatible with tissue, metals, polymers, elastomers, and sensitive electronics. ReliOx is advancing an initial wound cleansing and irrigation use case that aligns closely with military and emergency medicine needs, including contaminated wounds, blast injuries, and prolonged field care. The system’s on-demand architecture eliminates the need to store reactive disinfectants, reduces logistical burden, and supports distributed medical operations, a priority across DoD, BARDA, and ONR programs. This makes the platform particularly relevant for battlefield medicine, forward surgical teams, and humanitarian or disaster response scenarios. In parallel, ReliOx operates VetiOx, a veterinary-focused pathway that applies the same platform to animal wound care (including equine). This strategy generates early operational data and clinician familiarity while remaining aligned with long-term human medical translation—an approach consistent with MTEC’s emphasis on de-risking technologies prior to advanced development. The ReliOx platform is inherently dual-use. All commercial, veterinary, food safety, and medical applications share the same resin-based generation mechanism, enabling efficient manufacturing, rapid scaling, and consistent safety characteristics across use cases. This platform approach allows ReliOx to support incremental transition from non-regulated and veterinary markets into FDA-regulated medical devices and DoD-relevant medical countermeasures without fundamental redesign. ReliOx represents a strong MTEC-aligned opportunity at the intersection of advanced chemistry, trauma care, infectious disease mitigation, and distributed manufacturing. The company offers a defensible intellectual property position, a clear regulatory strategy, and a near-term path to operational relevance for military medicine and biodefense stakeholders .